934 related articles for article (PubMed ID: 19922807)
1. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
[TBL] [Abstract][Full Text] [Related]
2. Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study.
Kataoka K; Nannya Y; Ueda K; Kumano K; Takahashi T; Kurokawa M
Bone Marrow Transplant; 2010 Mar; 45(3):513-20. PubMed ID: 19684632
[TBL] [Abstract][Full Text] [Related]
3. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
[TBL] [Abstract][Full Text] [Related]
4. Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center.
Guilfoyle R; Demers A; Bredeson C; Richardson E; Rubinger M; Szwajcer D; Seftel MD
Bone Marrow Transplant; 2009 Jan; 43(2):133-9. PubMed ID: 18762762
[TBL] [Abstract][Full Text] [Related]
5. Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy.
Nakaya A; Mori T; Tanaka M; Tomita N; Nakaseko C; Yano S; Fujisawa S; Sakamaki H; Aotsuka N; Yokota A; Kanda Y; Sakura T; Nanya Y; Saitoh T; Kanamori H; Takahashi S; Okamoto S
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1553-9. PubMed ID: 25034961
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
Wang CY; Ren HY; Qiu ZX; Wang Y; Cen XN; Wang LH; Wang MJ; Xu WL; Wang WS; Li Y; Dong YJ; Ou JP; Liang ZY; Liu W; Wang Q
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
[TBL] [Abstract][Full Text] [Related]
7. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.
Barba P; Martino R; Pérez-Simón JA; Fernández-Avilés F; Castillo N; Piñana JL; López-Anglada L; Rovira M; Bosch F; Carreras E; Corral LL; Sierra J; Valcárcel D
Biol Blood Marrow Transplant; 2014 Jan; 20(1):66-72. PubMed ID: 24141006
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of risk assessment scores in patients with hematologic malignancies undergoing reduced-intensity conditioning allogeneic stem cell transplantation.
Yamamoto W; Ogusa E; Matsumoto K; Maruta A; Ishigatsubo Y; Kanamori H
Am J Hematol; 2014 Sep; 89(9):E138-41. PubMed ID: 24845702
[TBL] [Abstract][Full Text] [Related]
9. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation.
Bokhari SW; Watson L; Nagra S; Cook M; Byrne JL; Craddock C; Russell NH
Bone Marrow Transplant; 2012 Apr; 47(4):528-34. PubMed ID: 21743502
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in predicting outcomes for adolescents and young adults with hematologic malignancies undergoing allogeneic stem cell transplant.
Wood W; Deal A; Whitley J; Sharf A; Serody J; Gabriel D; Shea T
Pediatr Blood Cancer; 2011 Sep; 57(3):499-505. PubMed ID: 21384538
[TBL] [Abstract][Full Text] [Related]
11. The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation--investigation of potential limitations of the index.
Birninger N; Bornhäuser M; Schaich M; Ehninger G; Schetelig J
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1822-32. PubMed ID: 21708108
[TBL] [Abstract][Full Text] [Related]
12. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
[TBL] [Abstract][Full Text] [Related]
13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
15. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
16. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
17. A modified comorbidity index for hematopoietic cell transplantation.
DeFor TE; Majhail NS; Weisdorf DJ; Brunstein CG; McAvoy S; Arora M; Le CT
Bone Marrow Transplant; 2010 May; 45(5):933-8. PubMed ID: 19802025
[TBL] [Abstract][Full Text] [Related]
18. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
[TBL] [Abstract][Full Text] [Related]
19. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML.
Lim ZY; Ingram W; Brand R; Ho A; Kenyon M; Devereux S; Marsh J; Mufti GJ; Pagliuca A
Bone Marrow Transplant; 2010 Apr; 45(4):633-9. PubMed ID: 19767782
[TBL] [Abstract][Full Text] [Related]
20. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]